Rhumbline Advisers Increases Stock Position in DaVita Inc. (NYSE:DVA)

Rhumbline Advisers lifted its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 3.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 139,124 shares of the company's stock after purchasing an additional 4,999 shares during the period. Rhumbline Advisers owned about 0.18% of DaVita worth $21,282,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Copia Wealth Management purchased a new stake in DaVita during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. purchased a new stake in DaVita during the fourth quarter valued at approximately $41,000. Coppell Advisory Solutions LLC lifted its position in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after acquiring an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan purchased a new stake in DaVita during the fourth quarter valued at approximately $55,000. Finally, Venturi Wealth Management LLC lifted its position in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after acquiring an additional 152 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on DVA. Barclays increased their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Truist Financial decreased their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday, May 19th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, DaVita has an average rating of "Hold" and an average price target of $164.50.

DaVita Trading Up 0.1%

Shares of DaVita stock opened at $137.95 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12-month low of $131.76 and a 12-month high of $179.60. The firm has a market capitalization of $10.41 billion, a price-to-earnings ratio of 12.84, a PEG ratio of 1.07 and a beta of 1.11. The firm's 50 day simple moving average is $142.56 and its two-hundred day simple moving average is $152.14.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. DaVita's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.26 EPS. Analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.